Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Upstream Bio (UPB) EBITDA (2023 - 2025)

Upstream Bio has reported EBITDA over the past 3 years, most recently at -$46.2 million for Q4 2025.

  • Quarterly results put EBITDA at -$46.2 million for Q4 2025, down 75.42% from a year ago — trailing twelve months through Dec 2025 was -$160.4 million (down 106.21% YoY), and the annual figure for FY2025 was -$160.4 million, down 106.21%.
  • EBITDA for Q4 2025 was -$46.2 million at Upstream Bio, down from -$37.8 million in the prior quarter.
  • Over the last five years, EBITDA for UPB hit a ceiling of -$9.4 million in Q3 2023 and a floor of -$46.2 million in Q4 2025.
  • Median EBITDA over the past 3 years was -$22.6 million (2024), compared with a mean of -$26.2 million.
  • Peak annual rise in EBITDA hit 75.42% in 2025, while the deepest fall reached 152.83% in 2025.
  • Upstream Bio's EBITDA stood at -$14.3 million in 2023, then crashed by 83.66% to -$26.3 million in 2024, then crashed by 75.42% to -$46.2 million in 2025.
  • The last three reported values for EBITDA were -$46.2 million (Q4 2025), -$37.8 million (Q3 2025), and -$44.3 million (Q2 2025) per Business Quant data.